OINDPnews


Copley Scientific banner

Business

US federal judge rules that Teva’s mometasone furoate nasal spray does not infringe on Merck’s patent

On November 14, 2016, Judge Sue Robinson of the US District Court for the District of Delaware issued a ruling upholding Merck's US patent 6,127,353 but finding that Teva's mometasone nasal spray ANDA does not infringe the claims of that patent. Merck filed suit against Teva in July 2014 after Teva submitted an ANDA for the product to the FDA. Much of the … [Read more...] about US federal judge rules that Teva’s mometasone furoate nasal spray does not infringe on Merck’s patent

Pharmaxis partners with Woolcock Institute on development of tobramycin DPI

Pharmaxis will collaborate with the Woolcock Institute of Medical Research to develop a tobramycin dry powder inhaler for the treatment of cystic fibrosis, the company has announced. A A$421,545 grant from the Australian National Health and Medical Research Council (NHMRC) will fund the research to develop a dry powder formulation for delivery by Pharmaxis's Orbital … [Read more...] about Pharmaxis partners with Woolcock Institute on development of tobramycin DPI

Sanofi and MannKind finalize agreement on return of Afrezza rights

According to MannKind Corporation, it has reached an agreement with Sanofi regarding the return of rights to Afrezza inhaled insulin, in which "All issues arising out of the license and collaboration agreement, the supply agreement, the promissory note, the security agreement and the transition agreement are resolved." In January 2016, Sanofi announced that it … [Read more...] about Sanofi and MannKind finalize agreement on return of Afrezza rights

Aegis Therapeutics gets patent for octreotide nasal spray

The US Patent and Trademark Office (USPTO) has awarded US Patent No. 9,446,134 ("Stabilizing alkylglycoside compositions and methods thereof") to Aegis Therapeutics, the company said. The patent covers an intranasal formulation of octreotide, which is used to treat acromegaly and carcinoid syndrome. In July 2014, Aegis Therapeutics announced that it was looking to … [Read more...] about Aegis Therapeutics gets patent for octreotide nasal spray

Sumatriptan nasal spray shortage expected to be resolved by February 2017

According to an FDA drug shortages report, the US shortage of sumatriptan nasal spray due to a shortage of active ingredient that was first reported in November 2015 should be completely resolved by February 2017. At this time, both GlaxoSmithKline and Sandoz are reported to have 5 mg/spray versions of the nasal spray available, and GSK has the 20 mg product … [Read more...] about Sumatriptan nasal spray shortage expected to be resolved by February 2017

Medical Developments announces distribution deals, approval for Penthrox methoxyflurane inhaler

Purdue Pharma Canada will pay up to $3 million Canadian to Medical Developments International Limited (MDI) for Canadian rights to MDI's Penthrox methoxyflurane inhaler for the treatment of moderate to severe pain in trauma patients, and BL&H Co has obtained rights to the product in Korea, according to MDI. MDI also announced that Penthrox has been approved in the … [Read more...] about Medical Developments announces distribution deals, approval for Penthrox methoxyflurane inhaler

Orion to co-market Easyhaler DPIs with Menarini in several European countries

Orion Corporation has announced an agreement with Menarini Group to co-market its budesonide/formoterol Easyhaler DPI for the treatment of asthma and COPD in Germany, Italy, Spain, and Portugal. Each company will market the budesonide/formoterol inhaler under its own product name. Orion markets the DPI as Bufoler Easyhaler in the Netherlands, Fobuler in Italy, and … [Read more...] about Orion to co-market Easyhaler DPIs with Menarini in several European countries